As a provider of high-quality, cost-effective cellular and digital pathology services, we understand the importance of biomarkers in drug development and personalized medicine. By sponsoring the conference, we are demonstrating our dedication to supporting the biotech and pharmaceutical industries in their biomarker research efforts.
At the conference, attendees will have the opportunity to learn about the latest developments in biomarker discovery, validation, and qualification, as well as the use of biomarkers in drug development and personalized medicine. We are also excited to share our services at the exhibition and discuss how we can support the biomarker research needs of attendees.
We look forward to the opportunity to connect with industry leaders and experts in biomarker research at the Biomarkers Series UK conference. As sponsors, we are committed to promoting the advancement of biomarker research and advancing science. Learn more here.
27-28th Feb 2023
Barbara McManus, Michaela Downie, Tom Ashmore
As our Managing Director, Barbara is continuing to drive HistologiX’s strategic growth plan supporting biotherapeutic drug development and testing. She ensures the whole team continues to support our Clients’ needs thus building long term collaborative relationships. Barbara also has a focus on identifying opportunities to expand the niche services HistologiX offers.
Barbara began her scientific career within academic research institutes following her graduation from Strathclyde University, before moving into the contract testing industry. Barbara holds more than twenty years of invaluable Client and study management experience within the Life Sciences Sector and has worked for both large multinationals and small business start-ups.
Business Development Manager
Michaela is our Business Development Manager, responsible for strengthening relationships with existing clients and identifying new areas to grow the business. She has 20+ years of experience working globally with Biotech and Pharma Clients in Key Account and Business Development positions across the Life Sciences CRO sector.
Michaela began her scientific career at the University of Cambridge as a PostDoc in Dermatology, researching inflammatory skin diseases employing a variety of molecular and histology techniques including IHC and ISH. Michaela holds a PhD in Clinical Biochemistry from the University of Cambridge and a Diplom in Biology from the University of Cologne.
Business Development Executive
Tom’s focus in Business Development involves identifying new business opportunities and acting as the initial point of contact for companies seeking our cellular and digital pathology services. He is fully conversant in the range of services that HistologiX provides, and using his scientific and legal backgrounds, he discusses and helps design projects to meet our Clients’ analytical goals.
After working in PostDoc research roles with a focus on metabolic programming of obesity, diabetes and ageing, Tom trained in Intellectual Property Law in the pharma and biotech sectors. Tom has a 1st Class honours degree in Biochemistry from the University of Nottingham, and both a Masters and PhD from the University of Cambridge.